Search by Drug Name or NDC
NDC 51759-0202-22 AJOVY 225 mg/1.5mL Details
AJOVY 225 mg/1.5mL
AJOVY is a SUBCUTANEOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Teva Pharmaceuticals USA, Inc.. The primary component is FREMANEZUMAB.
MedlinePlus Drug Summary
Fremanezumab-vfrm injection is used to help prevent migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light). Fremanezumab-vfrm injection is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain natural substance in the body that causes migraine headaches.
Related Packages: 51759-0202-22Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Fremanezumab-vfrm Injection
Product Information
NDC | 51759-0202 |
---|---|
Product ID | 51759-202_0ca1b7ee-c1d4-40cc-b545-34d9acf767ad |
Associated GPIs | 6770203020D520 |
GCN Sequence Number | 080875 |
GCN Sequence Number Description | fremanezumab-vfrm AUTO INJCT 225 MG/1.5 SUBCUT |
HIC3 | H3F |
HIC3 Description | ANTIMIGRAINE PREPARATIONS |
GCN | 47862 |
HICL Sequence Number | 045236 |
HICL Sequence Number Description | FREMANEZUMAB-VFRM |
Brand/Generic | Brand |
Proprietary Name | AJOVY |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | fremanezumab-vfrm |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION |
Route | SUBCUTANEOUS |
Active Ingredient Strength | 225 |
Active Ingredient Units | mg/1.5mL |
Substance Name | FREMANEZUMAB |
Labeler Name | Teva Pharmaceuticals USA, Inc. |
Pharmaceutical Class | n/a |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA761089 |
Listing Certified Through | 2024-12-31 |
Package
NDC 51759-0202-22 (51759020222)
NDC Package Code | 51759-202-22 |
---|---|
Billing NDC | 51759020222 |
Package | 3 CONTAINER in 1 CARTON (51759-202-22) / 1.5 mL in 1 CONTAINER |
Marketing Start Date | 2020-08-31 |
NDC Exclude Flag | N |
Pricing Information | |
Price Per Unit | 471.573 |
Pricing Unit | ML |
Effective Date | 2024-01-01 |
NDC Description | AJOVY 225 MG/1.5 ML AUTOINJECT |
Pharmacy Type Indicator | C/I |
OTC | N |
Explanation Code | 4, 5 |
Classification for Rate Setting | B |
As of Date | 2024-02-21 |
This pricing file, entitled the NADAC (National Average Drug Acquisition
Cost) files, provide
state Medicaid agencies with covered outpatient drug prices by averaging
survey invoice
prices from retail community pharmacies across the United States. These
pharmacies include
independent retail community pharmacies and chain pharmacies. The prices
are updated on a
weekly and monthly basis